Debt ManagementNet Debt to Total Capital is 0%, indicating no debt burden.
Financial PerformanceThe company reported a cash balance of $189.3M, which was 97% above the company’s current market cap of approx. $96M.
Strategic FocusThe company continues to explore the potential for development of its norovirus vaccine candidates in adult patients, while exploring business development and strategic alternatives.